Literature DB >> 6199468

Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary.

R W Carlson, B I Sikic, M M Turbow, S C Ballon.   

Abstract

Nine women with germ-cell tumors of the ovary (three endodermal sinus tumors, four immature teratomas, and two mixed germ-cell tumors) were treated with cisplatin, vinblastine, and bleomycin (PVB) chemotherapy after cytoreductive operations. Five patients were stage I, three were stage III, and one patient had recurrent disease. All nine women are alive and without evidence of disease with a median follow-up of 31 months from diagnosis and 27 months since completion of PVB. Treatment toxicity although occasionally severe was rapidly reversible.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6199468     DOI: 10.1200/JCO.1983.1.10.645

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  NMR study of the effects of some bleomycin C-termini on the structure of a DNA hairpin with the 5'-GC-3' binding site.

Authors:  Teresa E Lehmann; Sally A Murray; Azure D Ingersoll; Teresa M Reilly; Shelby E Follett; Kevin E Macartney; Mark H Harpster
Journal:  J Biol Inorg Chem       Date:  2016-11-17       Impact factor: 3.358

2.  Interaction of Zn(II)bleomycin-A2 and Zn(II)peplomycin with a DNA hairpin containing the 5'-GT-3' binding site in comparison with the 5'-GC-3' binding site studied by NMR spectroscopy.

Authors:  Shelby E Follett; Azure D Ingersoll; Sally A Murray; Teresa M Reilly; Teresa E Lehmann
Journal:  J Biol Inorg Chem       Date:  2017-07-26       Impact factor: 3.358

3.  Solution structure of Fe(II)-azide-bleomycin derived from NMR data: transition from Fe(II)-bleomycin to Fe(II)-azide-bleomycin as derived from NMR data and structural calculations.

Authors:  Teresa Lehmann; Yang Li
Journal:  J Biol Inorg Chem       Date:  2012-04-06       Impact factor: 3.358

4.  Combination chemotherapy in malignant non-seminomatous germ-cell tumors: results of a cooperative study of the German Society of Pediatric Oncology (MAKEI 83).

Authors:  U Gobel; G Calaminus; R J Häas; H Jurgens; D Niethammer; J Ritter; H J Spaar; D Harms
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Dynamics of bleomycin interaction with a strongly bound hairpin DNA substrate, and implications for cleavage of the bound DNA.

Authors:  Trevor C Bozeman; Rupesh Nanjunda; Chenhong Tang; Yang Liu; Zachary J Segerman; Paul A Zaleski; W David Wilson; Sidney M Hecht
Journal:  J Am Chem Soc       Date:  2012-10-22       Impact factor: 15.419

6.  Structural study of copper(I)-bleomycin.

Authors:  Teresa E Lehmann
Journal:  J Biol Inorg Chem       Date:  2004-03-10       Impact factor: 3.358

7.  Prognostic significance of histopathological subtypes in stage I pure yolk sac tumour of the ovary.

Authors:  H Sasaki; M Furusato; S Teshima; T Kiyokawa; A Tada; S Aizawa; T Yamabe; S Tsugane; Y Terashima
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

Review 8.  The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.

Authors:  Vincent Murray; Jon K Chen; Long H Chung
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

Review 9.  Contributions of NMR to the understanding of the coordination chemistry and DNA interactions of metallo-bleomycins.

Authors:  Teresa Lehmann; Elena Topchiy
Journal:  Molecules       Date:  2013-08-02       Impact factor: 4.411

10.  Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences.

Authors:  Narges Zamani; Mohadese Rezaei Poor; Sedigheh Ghasemian Dizajmehr; Shima Alizadeh; Mitra Modares Gilani
Journal:  BMC Womens Health       Date:  2021-08-04       Impact factor: 2.809

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.